List of Excipients in Branded Drug TENOFOVIR DISOPROXIL FUMARATE

« Back to Dashboard

Generic Drugs Containing TENOFOVIR DISOPROXIL FUMARATE

Company	Ingredient	NDC	Excipient
Major Pharmaceuticals	tenofovir disoproxil fumarate	0904-6821	CELLULOSE, MICROCRYSTALLINE
Major Pharmaceuticals	tenofovir disoproxil fumarate	0904-6821	CROSCARMELLOSE SODIUM
Major Pharmaceuticals	tenofovir disoproxil fumarate	0904-6821	FD&C BLUE NO. 2 ALUMINUM LAKE

What are the Most Frequently-Used Excipients in TENOFOVIR DISOPROXIL FUMARATE?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	CALCIUM STEARATE
23	CELLULOSE, MICROCRYSTALLINE

Tenofovir Disoproxil Fumarate Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Tenofovir disoproxil fumarate (TDF) is a mature, globally genericized nucleotide reverse-transcriptase inhibitor used in HIV treatment, HIV pre-exposure prophylaxis (PrEP), chronic hepatitis B, and fixed-dose combinations. The strongest commercial opportunities are not in the active pharmaceutical ingredient itself. They are in low-cost, bioequivalent tablets; pediatric and dispersible presentations; differentiated adherence products; government and donor supply; and excipient systems that improve manufacturability, stability, swallowing, or taste.

TDF products have limited originator patent protection in the United States. The core commercial strategy is therefore cost, reliable supply, regulatory execution, and access to combination-product tenders rather than reliance on exclusivity.

What is tenofovir disoproxil fumarate and where is it used?

TDF is an oral prodrug of tenofovir. It is converted intracellularly to tenofovir diphosphate, which inhibits HIV reverse transcriptase and hepatitis B virus polymerase.

Attribute	TDF profile
Active ingredient	Tenofovir disoproxil fumarate
Therapeutic classes	Antiretroviral; anti-hepatitis B nucleotide analogue
Main indications	HIV-1 treatment, HIV PrEP, chronic hepatitis B
Common dosage form	Immediate-release oral tablet
Major combinations	Emtricitabine/TDF; efavirenz/emtricitabine/TDF; rilpivirine/emtricitabine/TDF; elvitegravir/cobicistat/emtricitabine/TDF
FDA originator products	Viread, Truvada, Atripla, Complera, Stribild
Biologic status	Not a biologic; biosimilar regulation does not apply
Generic pathway	Abbreviated New Drug Application, subject to bioequivalence and applicable product-specific requirements
Primary development constraint	Large tablet burden, high dose, renal safety considerations, and combination-product complexity

The FDA approved Viread in 2001 for HIV infection and later expanded its use to chronic hepatitis B. Truvada was approved in 2004 for HIV treatment and received FDA approval for PrEP in 2012. [1-3]

What excipients are used in TDF tablets?

The standard TDF excipient platform is conventional and inexpensive. The Viread 300 mg tablet label identifies lactose monohydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, and magnesium stearate as inactive ingredients. [1]

Core excipient functions

Excipient	Primary function in TDF tablets	Commercial relevance
Lactose monohydrate	Diluent and compression aid	Low cost, widely available; requires lactose labeling and control of moisture exposure
Microcrystalline cellulose	Diluent, dry binder, disintegration support	Supports direct compression and robust tablet hardness
Pregelatinized starch	Binder and disintegrant	Helps compensate for high drug loading and improve tablet breakup
Croscarmellose sodium	Superdisintegrant	Supports rapid disintegration despite a relatively large tablet
Magnesium stearate	Lubricant	Required at controlled levels because over-lubrication can slow dissolution

An excipient platform based on lactose, microcrystalline cellulose, starch, croscarmellose sodium, and magnesium stearate is commercially attractive because it uses globally available materials and established pharmaceutical compendial grades. It also limits formulation novelty that could trigger unnecessary regulatory or scale-up risk.

What excipient strategy is best for generic TDF tablets?

The preferred strategy is a robust immediate-release formulation with direct compression or a short granulation process, low tooling sensitivity, and dissolution performance that remains consistent across commercial-scale batches.

Direct-compression strategy

Direct compression can reduce processing steps, water exposure, and manufacturing cost. Microcrystalline cellulose and pregelatinized starch provide binding capacity, while croscarmellose sodium supports disintegration.

The main development risks are:

• Poor flow caused by high drug loading.
• Segregation between TDF and low-dose excipients.
• Sticking or picking during compression.
• Dissolution changes caused by excess magnesium stearate.
• Tablet weight and hardness variability.
• Sensitivity to humidity during storage.

A small amount of dry granulation or roller compaction may be preferable if the API has poor flow or segregation behavior. Wet granulation is technically feasible but may create unnecessary process complexity and expose the formulation to water.

Lactose-free strategy

A lactose-free formulation can target patients with lactose intolerance, procurement systems that prefer simplified excipient labeling, and markets where lactose-free claims have commercial value. Possible replacements include mannitol, dibasic calcium phosphate, spray-dried cellulose, or selected starch-based fillers.

The trade-offs include:

• Different tablet density and size.
• Potentially higher cost.
• Changed compactability.
• New dissolution and stability profiles.
• Additional control of polymorphic or hydrate behavior for inorganic fillers.

A lactose-free formulation is most commercially justified when it also improves tablet size, patient acceptability, or manufacturing performance. Removing lactose alone is unlikely to support a material price premium in standard generic channels.

Low-moisture strategy

TDF formulations should be evaluated for moisture sensitivity and packaging compatibility. A low-moisture excipient system may use anhydrous or low-moisture grades of selected diluents and stronger barrier packaging.

Commercial options include:

• High-barrier aluminum-aluminum blister packs.
• HDPE bottles with induction seals and desiccants.
• Moisture-controlled bulk packaging for government tenders.
• Moisture-resistant film coatings where needed.

Packaging can produce a larger stability benefit than a proprietary excipient change. The choice should be based on climatic-zone data, especially for products distributed in tropical and subtropical regions.

What formulations are protected by TDF patents?

The core TDF composition and use patents were developed by Gilead Sciences and its predecessors. Important historical U.S. patents associated with tenofovir prodrug technology and related products include U.S. Patent Nos. 5,922,743 and 6,043,230. Those core rights expired in the United States after the statutory patent term, with the principal protection period ending around 2018, subject to patent-specific adjustments and pediatric extensions. [4-6]

Protection category	Historical position	Current commercial effect
TDF active compound and prodrug technology	Core patents expired or reached the end of ordinary U.S. term	Low barrier for standard generic TDF
TDF tablet composition	Historical protection tied to originator products	Usually overcome by generic formulation and bioequivalence
TDF/FTC combinations	Combination and method patents had separate terms	Generic competition established in major markets
HIV treatment methods	Some historical method-of-use claims	Limited blocking effect where indications are off-patent
HIV PrEP use	Originator and public-interest patent disputes occurred	Generic and authorized-generic access expanded after settlements and licensing
Manufacturing processes	Process protection varies by jurisdiction	Can affect API sourcing and freedom to operate
TAF products	Separate, later-generation prodrug and formulation estate	TAF remains a different patent and commercial risk profile

Patent expiry must be checked country by country. European supplementary protection certificates, national validations, pediatric extensions, process patents, and combination claims can produce different dates from the United States.

What is the Orange Book status of TDF products?

TDF is an FDA-approved small molecule with listed reference products and approved generic versions. The FDA Orange Book identifies approved drug products, patents, and exclusivity information, but its entries can change as patents expire, delist, or become subject to regulatory updates. [7]

The practical Orange Book position is:

• Viread and Truvada are mature reference products.
• Generic TDF and emtricitabine/TDF products are established.
• No biosimilar pathway applies.
• Current generic applicants must comply with product-specific bioequivalence requirements.
• Paragraph IV risk is materially lower than it was during the originator exclusivity period.

A generic applicant that certifies against a listed patent can create Paragraph IV litigation risk. For mature TDF products, the principal commercial risk is generally regulatory execution, supply economics, or market access rather than a fundamental composition patent.

When did TDF lose exclusivity and when can generics launch?

The primary U.S. exclusivity period for TDF has ended. Generic entry occurred through multiple products and manufacturers after the core patent and regulatory barriers diminished.

Key U.S. milestones

Date	Event
2001	FDA approval of Viread
2004	FDA approval of Truvada
2006	FDA approval of Atripla
2012	FDA approval of TDF/FTC for PrEP
Around 2018	End of principal U.S. core patent term for major TDF technology, subject to patent-specific details
2020 onward	Broad generic availability and increasing substitution in many markets

Generic launch timing can differ by product. TDF monotherapy, TDF/FTC, and multi-drug combinations have separate ANDA requirements and may have different litigation histories.

What Paragraph IV challenges and litigation affected TDF?

TDF litigation was concentrated around Gilead’s core patents, combination products, and PrEP-related access. Generic manufacturers and public-interest organizations challenged patent scope, validity, or enforceability in different proceedings.

The commercial significance of Paragraph IV activity was highest before broad generic entry. After multiple approvals and patent expirations, litigation risk shifted toward product-specific claims, manufacturing patents, pediatric formulations, and combination-product patents.

Potential litigation areas include:

1. Invalidity challenges to composition or formulation claims.
2. Non-infringement arguments based on different excipient systems.
3. Patent-term calculations and pediatric exclusivity.
4. Combination-product claims covering TDF with emtricitabine or other antiretrovirals.
5. Method-of-use claims for HIV prevention or hepatitis B.
6. Process patents covering API synthesis or impurity control.

Historical settlements and licensing arrangements involving TDF-related products enabled earlier generic or authorized-generic access in selected countries. Their terms were often jurisdiction-specific and should not be treated as universal launch permissions.

What commercial opportunities exist for TDF excipients?

1. Low-cost generic tablets

This is the largest opportunity by volume. A supplier can compete through:

• Consistent compendial excipients.
• High-volume regional manufacturing.
• Technical support for direct compression.
• Lower variability in particle size and moisture.
• Reliable supply in Africa, Asia, Latin America, and other tender markets.

The commercial proposition is operational, not patent-based.

2. Pediatric formulations

Pediatric TDF has a stronger formulation opportunity than standard adult tablets. Useful formats include:

• Oral powder.
• Granules.
• Dispersible tablets.
• Smaller-dose tablets.
• Taste-masked multiparticulates.

The excipient system must address taste, dose flexibility, sedimentation, redispersibility, and caregiver handling. Mannitol, maltodextrin, microcrystalline cellulose, colloidal silicon dioxide, sweeteners, and flavor systems may be relevant, but each requires regulatory and palatability evaluation.

3. PrEP adherence products

TDF/FTC is used for PrEP, where adherence is a major commercial and public-health consideration. Opportunities include:

• Smaller tablets.
• Calendar or blister packaging.
• Clearly differentiated daily-use packaging.
• Low-cost 30-, 90-, and 180-day packs.
• Co-packaged testing or adherence-support systems where permitted.

Excipient differentiation alone is unlikely to justify a strong premium. Patient convenience and procurement integration are more defensible commercial levers.

4. Fixed-dose combinations

TDF is commonly commercialized in combinations. Excipient development must account for the total tablet mass, multiple APIs, dissolution interactions, and chemical compatibility.

TDF/FTC remains commercially important in generic HIV treatment and PrEP. Efavirenz/emtricitabine/TDF and other combinations can offer procurement value but have higher development complexity because of multiple APIs and potentially different dissolution requirements.

5. Government and donor procurement

Large-volume procurement favors:

• WHO-prequalified or nationally approved products.
• Stable three- to five-year supply capacity.
• Climatic-zone stability.
• Competitive unit economics.
• Packaging suitable for public-health distribution.
• API and excipient traceability.

For these channels, an excipient supplier can gain share by guaranteeing supply, validating alternate grades, and supporting rapid scale-up rather than by claiming a novel formulation.

How does TDF compare with tenofovir alafenamide?

TDF and tenofovir alafenamide (TAF) are different prodrugs with different patent and commercial profiles.

Factor	TDF	TAF
Development age	Older	Newer
Generic competition	Broad and established	More constrained by later patents and combinations
Typical tablet burden	Higher	Lower tenofovir dose in the product
Plasma tenofovir exposure	Higher	Lower
Renal and bone profile	Less favorable in some patients	Generally improved in approved settings
Excipient opportunity	Cost, pediatric, taste, stability	Patented formulations, fixed-dose combinations, specialized delivery
Market position	Access and volume	Differentiation and residual originator value

TAF is not a direct patent substitute for TDF. A company commercializing TDF should not assume that freedom to operate for TDF extends to TAF products or TAF-containing combinations.

How strong is the TDF patent estate?

The standard TDF patent estate is weak for blocking ordinary generic tablets in the United States because the principal composition and product patents have matured. It remains more complex in international markets and for particular combinations, methods, processes, and formulations.

A practical strength assessment is:

Area	Relative risk
Standard TDF tablet	Low in mature generic markets
TDF/FTC tablet	Low to moderate, depending on country and product claims
Pediatric or dispersible formulation	Moderate if new claims are pursued
Novel excipient composition	Moderate, but patentability and commercial value must be demonstrated
API manufacturing process	Moderate to high by jurisdiction
TAF-containing product	High relative to TDF
PrEP method-of-use claim	Country-specific and generally less important for routine generic supply

What generic launch risks exist for TDF?

The main launch risks are:

• Failure to demonstrate dissolution or bioequivalence.
• API impurity or residual-solvent failures.
• Inadequate stability under high humidity.
• Excessive tablet size.
• Poor compression performance.
• Insufficient capacity for large tenders.
• Inability to qualify alternate excipient suppliers.
• Country-specific patent or regulatory barriers.
• Price erosion after multiple generic approvals.
• Competition from TAF-based products in higher-income markets.

A commercial launch plan should prioritize one robust adult tablet, one combination product with clear demand, and a pediatric or dispersible extension only where procurement data supports the investment.

Key Takeaways

• TDF is a mature, genericized small-molecule product with limited U.S. exclusivity value.
• The standard excipient platform uses lactose, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, and magnesium stearate.
• Direct compression is attractive when API flow, segregation, and compression behavior are controlled.
• Lactose-free and low-moisture formulations can create targeted value, but they do not automatically support a premium.
• Pediatric dispersible, powder, and taste-masked formats offer the clearest formulation-development opportunities.
• TDF/FTC remains commercially relevant for generic HIV treatment and PrEP.
• Biosimilar risk does not apply because TDF is a small molecule.
• The main barriers are bioequivalence, stability, procurement economics, API supply, and jurisdiction-specific patent rights.
• TAF has a newer and stronger residual patent position and should be analyzed separately.

FAQs About TDF Excipient and Commercial Strategy

Can TDF tablets be made by direct compression?

Yes. A direct-compression platform using microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, and magnesium stearate is technically suitable, subject to API flow, blend uniformity, compression, and dissolution testing.

Is lactose necessary in TDF tablets?

No. Lactose is common in originator formulations but can be replaced with mannitol, starch-based fillers, dibasic calcium phosphate, or other suitable diluents. The replacement may change tablet size, hardness, dissolution, and stability.

What is the most attractive pediatric TDF formulation?

A taste-masked dispersible tablet, granule, or oral powder with dose flexibility is generally more differentiated than another adult immediate-release tablet. Regulatory acceptability, palatability, and dosing accuracy determine commercial viability.

Does a new TDF excipient combination create patent protection?

It can, but only if the formulation produces a patentable technical effect, such as unexpected stability, dissolution, bioavailability, manufacturability, or taste performance. Routine substitution of one compendial diluent for another is unlikely to provide strong patent protection.

Is TDF still commercially attractive despite generic price erosion?

Yes, where demand is supported by HIV treatment, PrEP, hepatitis B, government procurement, or donor-funded programs. Returns depend on manufacturing scale, tender access, supply reliability, and differentiated pediatric or combination products rather than on high unit pricing.

References

1. U.S. Food and Drug Administration. (2023). Viread (tenofovir disoproxil fumarate) prescribing information.

2. U.S. Food and Drug Administration. (2023). Truvada (emtricitabine/tenofovir disoproxil fumarate) prescribing information.

3. U.S. Food and Drug Administration. (2012). FDA approves first drug for reducing the risk of sexually acquired HIV infection.

4. U.S. Patent No. 5,922,743. (1999). Nucleotide analogues. United States Patent and Trademark Office.

5. U.S. Patent No. 6,043,230. (2000). Nucleotide analogues. United States Patent and Trademark Office.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

7. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.